CN110833528A - Lacosamide liposome freeze-dried powder injection and preparation method thereof - Google Patents
Lacosamide liposome freeze-dried powder injection and preparation method thereof Download PDFInfo
- Publication number
- CN110833528A CN110833528A CN201810937513.3A CN201810937513A CN110833528A CN 110833528 A CN110833528 A CN 110833528A CN 201810937513 A CN201810937513 A CN 201810937513A CN 110833528 A CN110833528 A CN 110833528A
- Authority
- CN
- China
- Prior art keywords
- lacosamide
- liposome
- freeze
- dried powder
- powder injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 title claims abstract description 40
- 229960002623 lacosamide Drugs 0.000 title claims abstract description 39
- 239000002502 liposome Substances 0.000 title claims abstract description 32
- 238000002347 injection Methods 0.000 title claims abstract description 27
- 239000007924 injection Substances 0.000 title claims abstract description 27
- 239000000843 powder Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 22
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 9
- 229930006000 Sucrose Natural products 0.000 claims abstract description 9
- 229960004793 sucrose Drugs 0.000 claims abstract description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 7
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 7
- 238000004108 freeze drying Methods 0.000 claims description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000008055 phosphate buffer solution Substances 0.000 claims description 5
- 239000003223 protective agent Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 abstract description 8
- 239000002245 particle Substances 0.000 abstract description 4
- 239000001961 anticonvulsive agent Substances 0.000 abstract description 3
- 229960003965 antiepileptics Drugs 0.000 abstract description 2
- 206010015037 epilepsy Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010061334 Partial seizures Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000006192 thin film tablet Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940089285 vimpat Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a lacosamide liposome freeze-dried powder injection and a preparation method thereof. The preparation method of the lacosamide liposome freeze-dried powder injection comprises the following components: 1-4 parts of lacosamide, 10-40 parts of soybean lecithin, 2-8 parts of cholesterol and 1.3-5.2 parts of cane sugar. The encapsulation efficiency of the lacosamide liposome prepared by the invention is more than 80%, the particle size is less than 200nm, the Zeta potential is less than-20 mV, and the pH value is 6.0-8.0. Lacosamide is a novel antiepileptic drug, the injection on the market at present is only suitable for replacing an oral preparation in a short period, and is used for patients who are not suitable for oral administration, the administration is carried out twice a day, and the injection frequency is too frequent.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a lacosamide liposome freeze-dried powder injection and a preparation method thereof.
Background
Epilepsy (epilesys), commonly known as epilepsy, is a chronic disease in which sudden abnormal discharges of cerebral neurons result in transient cerebral dysfunction. According to the latest Chinese epidemiological data, the total prevalence rate of domestic epilepsy is 7.0 per thousand, the annual incidence rate is 28.8/10 ten thousand, and the prevalence rate of active epilepsy with attacks within 1 year is 4.6 per thousand. Therefore, about 900 million epilepsy patients are estimated in China, 500-600 million of the epilepsy patients are active epilepsy patients, about 40 million epilepsy patients are newly added every year, and epilepsy has become the second most common disease of the neurology department, second to headache in China.
Lacosamide is a novel antiepileptic drug, a novel N-methyl-D-aspartate (NMDA) receptor glycine site binding antagonist developed by Schwarz BioSciences, a German subsidiary of the company British Yokoku (UCB Pharma). An NMDA receptor glycine site binding antagonist belongs to a new class of functional amino acids, and is an anticonvulsant drug with brand new dual mechanism action. It selectively promotes slow inactivation of sodium channels and modulates collapse response mediating protein 22(CRMP22), whereas CRMP22 may slow down or even stop seizures. Lacosamide tablets (english name: Lacosamide) approved by UCB corporation in european union of 9 months 2008 are marketed for the adjuvant treatment of partial seizures in patients with or without secondary grand mal seizures aged 16 years and older. Lacosamide has been approved by the FDA in the united states for marketing as an adjuvant drug in combination with other drugs for the treatment of partial seizures in patients over 17 years of age in 2008, month 10 under the trade name vimbat. Vimpat is approved for sale in 2 dosage forms, thin film tablets (50, 100, 150 and 200 mg/tablet), injectable solutions (10 mg/mL, 20 mL/vial).
The injection on the market at present is only suitable for replacing oral preparations in a short period and is used for patients who are not suitable for oral administration, but the injection is taken twice a day, the injection frequency is more frequent, and the medicine taking compliance of the patients is reduced. The liposome (Liposomes) is prepared from lecithin, ceramide and the like, has a bilayer structure which is the same as a skin cell membrane structure, is used as a good drug carrier, has the characteristics of wide drug loading range, high efficiency and low toxicity, can increase the stability and solubility of an encapsulated drug, endows the drug delivery characteristics such as drug slow release property and the like, and is a hotspot of research and application in multiple fields in recent years. In order to further improve the stability of the preparation in long-term storage and transportation, the lacosamide liposome solution is prepared into the lacosamide liposome freeze-dried powder injection through a freeze-drying process, and the preparation has good popularization prospect.
Disclosure of Invention
The invention aims to provide a lacosamide liposome freeze-dried powder injection which is safe and non-irritant and can realize long-acting slow-release administration.
The lacosamide liposome freeze-dried powder injection provided by the invention comprises the following components: 1-4 parts of lacosamide, 10-40 parts of phospholipid, 2-8 parts of cholesterol and 1.3-5.2 parts of cane sugar.
The lacosamide liposome freeze-dried powder injection provided by the invention has the advantages that the phospholipid is selected from one of soybean lecithin and egg yolk lecithin, and the soybean lecithin is preferred.
The lacosamide liposome freeze-dried powder injection provided by the invention uses one of sucrose, lactose and mannitol as a freeze-drying protective agent, and sucrose is preferred.
The buffer solution used by the lacosamide liposome freeze-dried powder injection provided by the invention is a phosphate buffer solution with the pH value of 6.0-8.0.
The preparation method of the lacosamide liposome freeze-dried powder injection comprises the following steps: dissolving lacosamide, phospholipid and cholesterol in ethanol, evaporating under reduced pressure to form a film, adding phosphate buffer solution, fully shaking the flask to make the lipid film hydrated and shed, emulsifying and ultrasonically processing to obtain liposome, adding freeze-drying protective agent into the liposome solution, and freeze-drying to obtain the final product.
The lacosamide liposome freeze-dried powder injection obtained by the technical scheme of the invention has the entrapment rate of more than 80 percent and the particle size of less than 200nm, and the preparation method has simple and convenient operation and good controllability and reproducibility. The lacosamide liposome freeze-dried powder injection for injection can obviously improve the storage stability, has the advantages of high encapsulation rate, good stability, low cost, good medicine taking compliance and the like, and has good popularization prospect.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to be limiting in any way.
Example 1:
| lacosamide | 1g |
| Soybean lecithin | 10g |
| Cholesterol | 2g |
| Sucrose | 1.3g |
Example 2:
| lacosamide | 2g |
| Egg yolk lecithin | 20g |
| Cholesterol | 4g |
| Lactose | 2.6g |
Example 3:
| lacosamide | 3g |
| Soybean lecithin | 30g |
| Cholesterol | 6g |
| Sucrose | 3.9g |
Example 4:
| lacosamide | 4g |
| Egg yolk lecithin | 40g |
| Cholesterol | 8g |
| Mannitol | 5.2g |
Comparative examples
| Lacosamide | 1g |
| Soybean lecithin | 8g |
| Cholesterol | 1g |
| Sucrose | 1.0g |
The preparation method comprises the following steps: dissolving lacosamide, phospholipid and cholesterol in ethanol, heating in water bath to 62 ℃, evaporating under reduced pressure to form a film, adding phosphate buffer solution, fully shaking the flask to enable a lipid film to be hydrated and shed, carrying out ultrasonic treatment on an emulsification probe for 3min to obtain liposome, adding a freeze-drying protective agent into the liposome solution, filtering, subpackaging in penicillin bottles, and carrying out freeze drying to obtain the lacosamide liposome freeze-dried powder injection.
The appearance shape, encapsulation rate and particle size of the liposome are used as evaluation indexes, and a Zetasizer nanometer laser particle size analyzer is used for measuring, wherein the measurement method of the encapsulation rate is as follows: encapsulation ratio (%) — actual drug content/actual total amount administered × 100%
TABLE 1 determination results of lacosamide liposome lyophilized powder for injection
| Appearance form | Encapsulation efficiency (%) | Zeta potential (mV) | |
| Example 1 | Pale yellow loose powder | 82.55 | -32.64 |
| Example 2 | Pale yellow loose powder | 82.29 | -35.19 |
| Example 3 | Pale yellow loose powder | 81.94 | -38.41 |
| Example 4 | Pale yellow loose powder | 81.99 | -36.82 |
| Comparative examples | Pale yellow loose powder | 62.37 | -15.27 |
As can be seen from the measurement results, the encapsulation efficiency of the samples in each example is more than 80%, the Zeta potential absolute value is more than 20mV, the stability is good, and the encapsulation efficiency and the Zeta potential are lower in the comparative example.
Claims (5)
1. A lacosamide liposome freeze-dried powder injection is composed of the following components: 1-4 parts of lacosamide, 10-40 parts of phospholipid, 2-8 parts of cholesterol and 1.3-5.2 parts of cane sugar.
2. The lacosamide liposome freeze-dried powder injection as claimed in claim 1, wherein: the phospholipid can be selected from soybean lecithin and yolk lecithin.
3. The lacosamide liposome freeze-dried powder injection as claimed in claim 1, wherein: the freeze-drying protective agent is one of sucrose, lactose and mannitol.
4. The lacosamide liposome freeze-dried powder injection as claimed in claim 1, which is characterized in that: the buffer solution is phosphate buffer solution with the pH value of 6.0-8.0.
5. The lacosamide liposome freeze-dried powder injection as claimed in claim 1, which is characterized by being prepared by the following method: dissolving lacosamide, phospholipid and cholesterol in ethanol, evaporating under reduced pressure to form a film, adding phosphate buffer solution, fully shaking the flask to make the lipid film hydrated and shed, emulsifying and ultrasonically processing to obtain liposome, adding freeze-drying protective agent into the liposome solution, and freeze-drying to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810937513.3A CN110833528A (en) | 2018-08-17 | 2018-08-17 | Lacosamide liposome freeze-dried powder injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810937513.3A CN110833528A (en) | 2018-08-17 | 2018-08-17 | Lacosamide liposome freeze-dried powder injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110833528A true CN110833528A (en) | 2020-02-25 |
Family
ID=69573499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810937513.3A Pending CN110833528A (en) | 2018-08-17 | 2018-08-17 | Lacosamide liposome freeze-dried powder injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110833528A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130251813A1 (en) * | 2010-12-02 | 2013-09-26 | Ucb Pharma Gmbh | Formulation of lacosamide |
| CN104771356A (en) * | 2014-01-09 | 2015-07-15 | 山东方明药业集团股份有限公司 | Lacosamide injection and preparation method thereof |
| CN104784134B (en) * | 2015-04-12 | 2018-05-29 | 石家庄四药有限公司 | A kind of scheme for lacosamide solid pharmaceutical preparation and preparation method thereof |
| CN105663060B (en) * | 2016-02-23 | 2018-08-14 | 广西梧州制药（集团）股份有限公司 | A kind of dianhydrogalactitol lipidosome freeze-dried injection and preparation method thereof |
-
2018
- 2018-08-17 CN CN201810937513.3A patent/CN110833528A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130251813A1 (en) * | 2010-12-02 | 2013-09-26 | Ucb Pharma Gmbh | Formulation of lacosamide |
| CN104771356A (en) * | 2014-01-09 | 2015-07-15 | 山东方明药业集团股份有限公司 | Lacosamide injection and preparation method thereof |
| CN104784134B (en) * | 2015-04-12 | 2018-05-29 | 石家庄四药有限公司 | A kind of scheme for lacosamide solid pharmaceutical preparation and preparation method thereof |
| CN105663060B (en) * | 2016-02-23 | 2018-08-14 | 广西梧州制药（集团）股份有限公司 | A kind of dianhydrogalactitol lipidosome freeze-dried injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180353463A1 (en) | Cannabinoid Formulations | |
| US9827260B2 (en) | Composition for buffered aminoalkyl glucosaminide phosphate compounds and its use for enhancing an immune response | |
| US12233044B2 (en) | Cannabidiol and chitosan compositions and methods of using the same | |
| CN116173188A (en) | Oral GLP-1 analogue solid lipid nanoparticles and its preparation method and application | |
| CN101057674B (en) | Composition for preventing and curing diabetes | |
| US20240201140A1 (en) | Method for the analysis of related substances in cyclosporine a preparation, and use thereof | |
| CN110833528A (en) | Lacosamide liposome freeze-dried powder injection and preparation method thereof | |
| CA3147335A1 (en) | Methods for increasing the bioavailability of otc and pharmaceutical drugs | |
| Semele et al. | From traditional medicine to advanced therapeutics: the renaissance of phyto-nano interventions in psoriasis | |
| JP2021031472A (en) | APEH production promoter | |
| CN105228614A (en) | Be used for the treatment of combined therapy agent and the method for neurodegenerative disease and Other diseases | |
| KR20210058760A (en) | Composition for preventing or treating renal disease comprising Zizyphus jujuba MILL extract | |
| CN105663060B (en) | A kind of dianhydrogalactitol lipidosome freeze-dried injection and preparation method thereof | |
| CN118680917B (en) | A composition containing oseltamivir phosphate and its use in preparing antiviral drugs | |
| US20240342234A1 (en) | Encapsulated phytomedicines for use against cancer | |
| US20250222017A1 (en) | Methods of using avermectin compositions for the treatment of neurological disorders and dosing regimens | |
| JP2016537428A (en) | Ephedra arata extract and method of use | |
| US20250195552A1 (en) | Methods of using avermectin compositions for the treatment of inflammatory disorders and dosing regimens | |
| US20160296574A1 (en) | Ephedra alata extracts and methods of use thereof | |
| KR20110031599A (en) | Inflammatory disease prevention and treatment composition containing the extract of Eliokapus petioratus | |
| EP3903776A1 (en) | Composition for improving cognitive function | |
| CN102085183B (en) | Asarin lipid nanospheres and method for preparing same | |
| SI26055A (en) | Nano-micellar pharmaceutical synergetic composition with antioxidant, anti-inflammatory, immunomodulating, antiviral properties for multiple therapeutic applications | |
| CN113874029A (en) | CP 2C-targeting peptide-based anticancer agents | |
| CA2996901A1 (en) | Composition for treating and preventing viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200225 |